Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir

Cancer Research

Volumn 61, Issue 13, 2001, Pages 5057-5064

  Liekens, Sandra ^a   Neyts, Johan ^a   De Clercq, Erik ^a   Verbeken, Erik ^b   Ribatti, Domenico ^c   Presta, Marco ^d  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACYCLIC NUCLEOSIDE; CIDOFOVIR; PHOSPHONIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASCULAR TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL DIVISION; CHICK EMBRYO; CYTOSINE; ENDOTHELIUM, VASCULAR; FEMALE; FIBROBLAST GROWTH FACTOR 2; HEMANGIOENDOTHELIOMA; MICE; MICE, NUDE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0035394723     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. A novel selective broad-spectrum anti-DNA virus agent
2. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines
3. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome
4. Antiviral drug susceptibility of human herpesvirus 8
5. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy
6. In search of a selective antiviral chemotherapy
7. A new topical treatment for resistant herpes simplex infections
8. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS
9. A multicenter Phase I/II dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes
10. Successful resolution of progressive multifocal leukoencephalopathy after combination therapy with cidofovir and 1-β-D-arabinofuranosylcytosine
11. Response to cidofovir after failure of antiretroviral therapy alone in AIDS-associated progressive multifocal leukoencephalopathy
12. Topical intralesional cidofovir: A review of pharmacology therapeutic effects
13. Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Veto cells
14. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells
15. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates
16. HPMPC (cidofovir). PMEA (adefovir), and related acyclic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in the treatment of viral infections
17. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation
18. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]
19. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue
20. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (C1N III)
21. Topical cidofovir for severe molluscum contagiosum
22. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir
23. Treatment of classical Kaposi's sarcoma with intralesional injections of cidofovir: Report of a case
24. Clinical pharmacokinetics of the antiviral nucleotide analogue cidofovir and adefovir
25. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1
26. Inhibiting effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic nude mice
27. The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-posphonyl-methoxypropyl)cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice
28. A novel animal model for hemangiomas: Inhibition of hemangioma development by the angiogenesis inhibitor TNP-470
29. Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir
30. A flanking attack on cancer
31. Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production. DNA synthesis and migration
32. Endogenous basic fibroblast growth factor is implicated in the vascularization of the chick embryo chorioallantoic membrane
33. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the ανβ3 integrin
34. Cellular markers that distinguish the phases of hemangioma during infancy and childhood
35. Endothelial cells overexpressing basic fibroblast growth factor (FGF-2) induce vascular tumors in immunodeficient mice
36. Basic fibroblast growth factor overexpression in endothelial cells: An autocrine mechanism for angiogenesis and angioproliferative diseases
37. Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factor-2
38. Rate of basement membrane biosynthesis as an index to angiogenesis
39. Neovascular response induced by cultured aortic endothelial cells
40. Treatment of adenoviral conjunctivitis with topical cidofovir
41. (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir). Results of a Phase I/II study of a novel antiviral nucleotide analogue
42. Epstein-Barr virus latent membrane protein I blocks p53-mediated apoptosis through the induction of the A20 gene
43. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
44. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses
45. J domain-independent regulation of the Rb family by polyomavirus large T antigen
46. Insights into cancer from transgenic mouse models
47. Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process
48. Antiangiogenesis is produced by nontoxic doses of vinblastine
49. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
50. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
51. Ara-C: Cellular and molecular pharmacology
52. Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway
53. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells
54. S-phase accumulation precedes apoptosis induced by preoperative treatment with 5-fluorouracil in human colorectal carcinoma cells
55. Antitumor potential of acyclic nucleoside phosphonates
56. In vitro sensitivity of Kaposi's sarcoma cells to various chemotherapeutic agents including acyclic nucleoside phosphonates